Background {#Sec1}
==========

Systemic fungal infections have emerged as a significant public health problem \[[@CR1]\]. Among hospitalized patients, candidaemia is the most common form of invasive candidiasis (IC), which accounts for 9% of all nosocomial bloodstream infections (BSIs) \[[@CR2], [@CR3]\]. In a 2014 United States (US) surveillance study, *Candida* species ranked as the seventh causative organism of healthcare-associated BSIs \[[@CR4]\]. Recent reports indicated that candidaemia is the third or fourth most common hospital-acquired BSI in US hospitals \[[@CR5]\]. *Candida* species are considered the leading pathogen in many fungal infections affecting humans. Among 15 distinct *Candida* species causing human disease, *C. albicans, C. glabrata, C. tropicalis, C. parapsilosis* and *C. krusei* are the most common pathogens leading to IC \[[@CR5]\].

Risk factors associated with antifungal resistance have been addressed in many studies. Previous fluconazole exposure, neutropenia and chronic kidney disease are known to contribute to *C. albicans* fluconazole resistance \[[@CR6]\]. However, total parental nutrition, previous episodes of candidaemia and the presence of fluconazole-resistant isolates were mainly accompanied by echinocandin resistance \[[@CR7]\]. In Saudi Arabia, many studies have described the distribution and risk factors for *Candida* BSI; however, there are no local studies on the risk factors associated with antifungal resistance and its effect on mortality. *C. albicans* were the most commonly isolated *Candida* among all studies conducted in Saudi Arabia \[[@CR8]--[@CR11]\]. Predisposing factors related to candidaemia occurrence were related to use of a central venous catheter, previous use of broad-spectrum antibiotics and complicated abdominal surgeries; the mortality rate was 43% for all candidaemia cases \[[@CR9]\]. Therefore, our study was conducted to identify the occurrence of antifungal-resistant candidaemia, describe the distribution of *Candida* species among hospitalized patients with candidaemia, determine the risk factors associated with antifungal resistance and evaluate the association of antifungal resistance with length of ICU and hospital stay and with 30-day mortality.

Methods {#Sec2}
=======

Setting and study design {#Sec3}
------------------------

A retrospective cohort study was conducted at King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia (KFSH&RC-J), a 500-bed teaching and tertiary care hospital. The study was approved by the hospital institutional review board. Between January 2006 and December 2017, all adult patients 18 years old and above with isolated *Candida* BSI with or without other forms of IC were included. IC included disseminated hepatosplenic candidiasis, intra-abdominal candidiasis, *Candida* intravascular infection, osteoarticular candidiasis, *Candida* endophthalmitis, vulvovaginal candidiasis, *Candida* urinary tract infection, oropharyngeal candidiasis, oesophageal candidiasis or central nervous system candidiasis \[[@CR5]\]. The study excluded patients under 18 years of age and those infected with IC alone in the absence of candidaemia. Patients with candidaemia were reviewed through hospital electronic charts. The REDCap system was used to collect patient information, such as patient demographics and comorbidities. Baseline characteristics and *Candida* distribution were assessed for all patients with *Candida* BSI. Patients with available susceptibility data were divided into two groups: antifungal-sensitive and antifungal-resistant; risk factor and mortality analyses were performed. Antifungal resistance was considered for any identified isolate with resistance to one or more antifungals based on the laboratory cut-off value of minimum inhibitory concentration (MIC).

The primary outcome was the occurrence of antifungal resistance among candidaemia patients over a 12-year study period. The secondary outcomes were the distribution of *Candida* BSI, the risk factors for antifungal resistance and the association of antifungal resistance with length of ICU and hospital stay and with 30-day mortality.

Microbiology {#Sec4}
------------

The identification of *Candida* BSI was consistent throughout the study period. Identification was performed by a blood culture test and processed by using the automated blood culture system BACTEC FX. The average incubation period was 5 days and reaches up to 21 days whenever candidaemia is suspected. The API 20C AUX Kit was used for identification and specification of yeast, and Sensititre YeastOne was used for susceptibility. The MICs for fluconazole, voriconazole, itraconazole, posaconazole, amphotericin B, flucytosine, caspofungin, anidulafungin and micafungin were interpreted based on the Clinical and Laboratory Standard Institute (CLSI M27-S4). As the interpretation of the amphotericin B susceptibility breakpoint has not yet been defined \[[@CR12]\], our study did not address amphotericin B susceptibility testing for *Candida* BSI.

Statistical analysis {#Sec5}
--------------------

Data were analysed using SAS version 9.4. Descriptive statistics using the mean, median and interquartile range (IQR) were used for continuous variables. Frequencies and percentages were used for categorical variables. The chi-square test and Fisher's exact test were used to compare categorical variables. For risk factor analysis of antifungal resistance, we performed a univariate logistic regression analysis. For 30-day mortality, we performed univariate and multivariable analyses to identify factors associated with mortality. A *P* value less than 0.05 was considered significant.

Results {#Sec6}
=======

From January 2006 to December 2017, a total of 196 *Candida* species were identified in 189 patients. Demographic characteristics and risk factors associated with resistant *Candida* BSI are listed in (Table [1](#Tab1){ref-type="table"}). The most common *Candida* species during the study period was *C. glabrata* (*n* = 59, 30.1%). Distributions of *Candida* species are included in (Table [2](#Tab2){ref-type="table"}). Table. Table 1Baseline characteristics for patients with candida bloodstream infection (BSIs)CharacteristicsNumber of Patients (*N* = 189)\
n (%)Mean Age (years)57.3 ± 17.5Gender Male94 (49.74%) Female95 (50.26%)Bacteremia co-infection79 (41.8%)Baseline Comorbidities Diabetes99 (52.38%) Hypertension105 (55.56%) Chronic kidney disease24 (12.7%) Liver Cirrhosis33 (17.46%) Cardiovascular diseases96 (50.79%) Lung diseases52 (27.51%) Human immunodeficiency virus3 (1.59%) Solid organ transplantation8 (4.23%) Hematological malignancy9 (4.76%) Non hematological malignancy48 (25.4%) Neutropenia ^a^25 (13.23%) History of IV drug user3 (1.59%) Blood/ Platelet transfusion135 (71.43%) Recent hospital admission35 (18.52%)Exposure to medication within 3 months ^a^ Broad spectrum antibiotics182 (96.3%) Polyene antifungal3(1.59%) Azole antifungal (Fluconazole)11 (5.82%) Echinocandins38 (20.11%) Corticosteroids86 (45.5%)Exposure to medical procedures within 3 months TPN20 (10.58%) Central line insertion151 (79.89%)Urine catheter148 (78.31%)Invasive Ventilation100 (52.91%)Surgery within 3 months77 (40.74%) GI38 (49.35%) Non- GI39 (50.65%)Renal Replacement therapy66 (34.92%)HD54 (28.57%)PD4 (2.12%)CRRT11 (5.82%)SLID4 (2.12%)Total parental nutrition (TPN); Gastrointestinal (GI); Hemodialysis (HD); Peritoneal dialysis (PD); Continuous renal replacement therapy (CRRT); Sustained low efficiency dialysis (SLID); Intravenous (IV);^a^Neutropenia defined as an absolute neutrophil count of, 1.0 10^9^/L or less; N = total number of patients; n = number of patients or events Table 2Distribution of *Candida* Species over the study period*Candida* isolatesTotal number of isolates (*N* = 196)\
n(%)*C. glabrata*59 (30.1)*C. albicans*46 (23.47)*C. parapsilosis*38 (19.39)*C. tropicalis*35 (17.86)*C. krusei*6 (3.06)*C. famata*5 (2.55)*C. lusitaniae*1 (0.51)*C .kefyr*1 (0.51)*C. dubliniensis*1 (0.51)*C. trichosporon asahii*1 (0.51)Others3 (1.53)

One hundred and twenty-two patients with antifungal susceptibility data were analysed in the candidaemia resistance risk factor analysis (Table [3](#Tab3){ref-type="table"}); the percentage of antifungal resistance was 21% (26/122). Candidaemia with antifungal resistance was significantly more likely to develop among patients with previous echinocandin exposure (odds ratio (OR), 1.38; 95% CI (1.02--1.85); *P* = 0.006) and in patients who received invasive ventilation (OR, 1.3; 95% CI (1.08--1.57); *P* = 0.005). Table 3Univariate regression analysis for risk factors associated with antifungal resistance candidemiaAntifungal sensitive\
(*N* = 96)Antifungal resistance\
(*N* = 26)OR (95% CI)*P* valueAge (years)Mean ± SD58.7 ± 16.256.5 ± 20.29Gender, n (%) Male53 (55.21)10 (38.46)0.5 (0.2_1.23)0.12 Female43 (44.79)16 (61.54)Comorbidities, n (%) Diabetes61 (63.54%)15 (57.69%)0.94 (0.77_1.15)0.58 Hypertension56 (58.33%)16 (61.54%)1.02 (0.85_1.23)0.76 Chronic Kidney disease14 (14.58%)4 (15.38%)1.01 (0.77_1.32)0.91 Liver Cirrhosis10 (10.42%)4 (15.38%)1.11(0.78_1.57)0.48 Cardiovascular disease44 (45.83)16 (61.54)1.14(0.94_1.37)0.15 Lung diseases24 (25%)6 (23.08%)0.97 (0.79_1.2)0.83 Solid organ transplantation2 (2.08%)2 (7.69%)1.59 (0.59_4.26)0.15 Hematological malignancy2 (2.08%)0 Non Hematological malignancy35 (36.46%)2 (7.69%)0.75 (0.65_0.88)0.004 Neutropenia7 (7.29%)4 (15.38%)1.09 (0.31_3.79)0.88 History of IV drug user2 (2.08%)1 (3.85%)1.18 (0.52_2.65)0.63-months exposure before candidemiaBlood/ Platelet transfusion60 (62.5%)20 (76.92%)1.14 (0.95_1.36)0.16Recent hospital admission20 (20.83%)8 (30.77%)1.13 (0.87_1.45)0.28Broad spectrum antibiotics90 (93.75%)26 (100%)1.28 (1.16_1.42)0.19Polyene antifungal3 (3.13)00.78 (0.71_0.85)0.36Azole antifungal (fluconazole)8 (8.33%)1 (3.85%)0.87 (0.68_1.12)0.43Echinocandins19 (19.79%)12 (46.15%)1.38 (1.02_1.85)0.006Corticosteroids52 (54.17%)19 (73.08%)1.17 (0.98_1.4)0.08TPN13 (13.54%)4 (15.38%)1.03 (0.78_1.36)0.81Central catheter insertion71 (73.96%)21 (80.77%)1.07 (0.88_1.31)0.47Urine catheter73 (76.04%)17 (65.38%)0.88 (0.69_1.12)0.27Invasive Ventilation44 (45.83%)20 (76.92%)1.3 (1.08_1.57)0.005Previous surgery38 (39.58%)14 (53.85%)1.13 (0.93_1.37)0.19 GI21(55.26%)4 (28.5%)1.08 (0.88_1.31)0.42 Non- GI17 (44.7%)10 (71.4%)Renal Replacement therapy36 (37.5%)12 (46.15%)1.08 (0.88_1.31)0.42 HD26 (27.08)12 (46.15)1.21 (0.96_1.54)0.06 PD3 (3.13)0 CRRT9 (9.38)0 SLID2 (2.08)2 (7.69)1.59 (0.59--4.2)0.15Odd ratio (OR); Confidence interval (CI); Total parental nutrition (TPN); Gastrointestinal (GI); Hemodialysis (HD); Peritoneal dialysis (PD); Continuous renal replacement therapy (CRRT); Sustained low efficiency dialysis (SLID) N = total number of patients; n = number of patients or events

Cross-resistance among azole antifungals was observed in our study. All strains resistant to voriconazole, including five strains of *C. albicans*, two strains of *C. parapsilosis* and one strain of *C. tropicalis,* were also resistant to fluconazole. Only two isolates were resistant to caspofungin, and three isolates were resistant to anidulafungin (Additional file [1](#MOESM1){ref-type="media"}: Tables S1 and S2).

The median (interquartile range \[IQR\]) length of ICU stay was 29 days \[range 12--49 days\] in the antifungal-resistant group and 18 days \[range 6.7--37.5 days\] in the antifungal-sensitive group (*P* = 0.28). The median \[IQR\] length of hospital stay was 51 days \[range 21--138 days\] in the antifungal-resistant group and 35 days \[range 17--77 days\] in the antifungal-sensitive group (*P* = 0.09). Thirty-day mortality was 15 (57.7%) and 54 (56.25%) for the antifungal-resistant and antifungal-sensitive groups, respectively \[OR = 1.01; 95% CI (0.84--1.21); *P* = 0.89\] (Table [4](#Tab4){ref-type="table"}). Table 4Outcome analysis for patients with antifungal resistance candidemiaAntifungal sensitive\
(*N* = 96)One or more antifungal resistance\
(*N* = 26)*P* ValueLength of ICU Stay (*n* = 84), Median (IQR)18 (6.7 \_ 37.5)29 (12 \_ 49)0.28Length of hospital stay (days) Median (IQR)35 (17\_ 77)51.5 (21\_ 138)0.09Mortality before first negative culture n (%)26 (27.08)5 (19.23)0.4130-day mortality n (%)54 (56.25)15 (57.69)0.89Interquartile range (IQR), N = total number of patients; n = number of patients or events

In a multivariate logistic regression analysis used to assess factors associated with mortality in patients with candidaemia, the following factors were independently associated with mortality. Liver cirrhosis \[OR = 5.36; 95% CI (1.14--25.1)\], non-haematological malignancy \[OR = 2.3; 95% CI (1.01--5.25)\], blood/platelet transfusion \[OR = 4.4; 95% CI (1.98--9.7)\], central venous catheter \[OR = 4.37; 95% CI (1.79--10.66)\] and invasive ventilation \[OR = 3.88; 95% CI (1.82--8.29)\] (Additional file [1](#MOESM1){ref-type="media"}: Table S3).

We performed a secondary analysis for patients with fluconazole-resistant *C. parapsilosis* to identify risk factors for resistance. Univariate analysis revealed that echinocandin exposure \[OR = 12.8; 95% CI (2.01--81.10)\], blood/platelet transfusion \[OR = 14.6; 95% CI (1.54--138.18)\] and invasive ventilation \[OR = 2.1; 95% CI (1.31--3.39)\] were associated with fluconazole-resistant *C. parapsilosis* (Table [5](#Tab5){ref-type="table"}). Table 5Univariate regression analysis for statistically significant risk factors associated with fluconazole resistance C.*parapsilosis* in patients with candidemiaFluconazole sensitive *C.parapsilosis*\
(*N* = 20)Fluconazole resistance *C.parapsilosis*\
(*N* = 10)OR (95%CI)*P* ValuePrevious Echinocandin Exposure5 (23.81%)8 (80%)12.8 (2.01_81.1)0.005Blood and Platelet Transfusion7 (35%)9 (90%)14.6 (1.54_138.18)0.006Invasive Ventilation9 (42.8%)10 (100%)2.1 (1.31_3.39)0.004Odd ratio (OR), N = total number of patients

Discussion {#Sec7}
==========

Worldwide, there has been a notable shift away from *C. albicans* among patients with *Candida* BSI \[[@CR13]\]. Our study showed a high frequency in non-*C. albicans* candidaemia (Fig. [1](#Fig1){ref-type="fig"}). These strains had a higher cost and length of hospital stay than *C. albicans* \[[@CR14]\]. *C. glabrata* was the predominantly isolated *Candida* species among our candidaemia patients, representing 30 % of cases, followed by *C. albicans* and *C. parapsilosis*. These findings differ from those of previous local studies. Two studies conducted in Saudi Arabia in a university hospital and armed force hospital between 1998 to 1999 and 1996 to 2002 concluded that *C. albicans* was the most commonly isolated *Candida* species among patients with candidaemia, followed by *C. tropicalis* and *C. parapsilosis* \[[@CR8], [@CR11]\]. Moreover, *C. albicans* remained the dominant isolated species among candidaemia cases in many studies \[[@CR1], [@CR2], [@CR15], [@CR16]\]. Geographic variation significantly affects the species distribution of *Candida* \[[@CR2]\]. A systematic review summarizing the distribution of *Candida* species found a high concentration of *C. albicans* isolates in Northern and Central Europe in addition to the USA; however, non*-C. albicans* species were more common in South America, Asia and Southern Europe \[[@CR17]\]. Fig. 1Distribution of *Candida* Species over the study period

Antifungal resistance is a growing primary concern for most healthcare providers. We analysed one hundred and twenty-two *Candida* BSI cases for resistance. Twenty-one percent of all isolates were resistant to one or more antifungal agents. The patient's risk of developing antifungal resistance was a primary concern in our study. We looked for many possible predisposing factors for drug insensitivity 90 days prior to a candidaemia episode. Patient's previous exposures to broad-spectrum antibiotics, antifungals and corticosteroids were reported; none of the aforementioned risk factors showed a significant association with antifungal resistance in our study despite a positive association of previous antimicrobial exposure to fluconazole resistance among candidaemia in a previous study \[[@CR18]\]. However, previous exposure to echinocandins was significantly associated with antifungal resistance among our patients. Many researchers have confirmed that decreased susceptibility to *Candida* is significantly associated with previous antifungal exposure and an inappropriate prior course of antifungal therapy \[[@CR6], [@CR19], [@CR20]\]. In fact, fluconazole exposure was found to be a risk factor for gene mutation and overexposure that leads to future fluconazole-resistant *C. parapsilosis* \[[@CR21]\]. Furthermore, we investigated patient comorbidities and history of invasive procedures or surgery. Many studies addressed drug-resistant candidaemia among cancer patients and considered them a high-risk group \[[@CR22]\]. However, our cohort found that antifungal resistance was low among candidaemia patients with non-haematological malignancy. On the other hand, invasive ventilation was significantly associated with drug resistance; this result has been concluded by many researchers, who found that *Candida* resistance is dramatically higher among critical-care patients \[[@CR17]\].

*C. parapsilosis* is known to have a high affinity for fluconazole, and resistance was absent in an earlier prospective trial \[[@CR23]\]. In our study, up to 33 % of *C. parapsilosis* strains were insensitive to fluconazole. Clinical resistance to echinocandins is rare; however, some cases of caspofungin resistance in patients with prolonged exposure to echinocandins have been reported \[[@CR13]\]. Our study found few cases of echinocandin resistance. A 2012 US study investigated changes in the incidence of antifungal drug resistance, showing a 7% resistance to fluconazole and only 1% to echinocandin \[[@CR15]\]. In a US multicentre candidaemia surveillance programme, an increase in the rate of echinocandin resistance was mainly found in *C. glabrata*, despite it being the preferred treatment \[[@CR7]\]. Indeed, patients with fluconazole resistance were at higher risk for *C. glabrata*-associated echinocandin resistance \[[@CR16]\]. The variation in antifungal resistance patterns across geographic regions was addressed in a report on SENTRY antimicrobial surveillance, which observed a detectable resistance to anidulafungin, micafungin, and azoles among isolates of *C. glabrata* from North America \[[@CR24]\].

*Candida* BSI contributed to a prolonged hospital stay and an increase in the overall healthcare cost \[[@CR2]\]. Furthermore, drug resistance was associated with overall mortality \[[@CR10], [@CR22]\]. Despite the increase in length of hospital stay and mortality among our patients with antifungal resistance, the results were not significant.

The retrospective nature of our study could prevent us from identifying all risk factors related to our candidaemia cases. Data on source control and appropriateness of antifungal treatment in terms of timing and dosing of antifungals were not included in our study. Patients who transferred from an outside hospital had no previous records in our system, and risk factors were identified only by physician evaluation notes and nurse documentation. Another limitation is the unavailability of susceptibility data between 2006 and 2011 for all *Candida* species isolated during our study period, as the request for data was sent out and performed only upon physician request. Although KFSHRC-J is a bone marrow transplantation centre, the number of patients with haematological malignancies involved in our study was small, which prevents us from investigating fluconazole pre-exposure as a risk factor for drug-resistant candidaemia.

Conclusions {#Sec8}
===========

The study identified a high frequency of non-*albicans* candidaemia. The rise in fluconazole-resistant *C. parapsilosis* is alarming. More regional data from different hospital settings are needed to allow for a comparison of findings. Our study emphasizes the importance of implementation and compliance with antimicrobial stewardship programmes to control antifungal utilization among hospitalized patients.
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**Additional file 1: Table S1.** Resistance pattern among candidemia patients with available susceptibility data by *Candida* isolates. **Table S2.** Resistance pattern among candidemia patients with available susceptibility data by antifungal group. **Table S3.** Multivariate regression analysis for the statistically significant risk factors affecting mortality in patients with antifungal resistance candidemia.
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